On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive ...
Sanofi is rolling out a new global campaign that features the stories of six real patients, to underscore its core purpose.
Roche has built the evidence for its oral BTK inhibitor fenebrutinib in multiple sclerosis (MS) with two phase 3 readouts ...
Paris, September 22, 2025. The US Food and Drug Administration (FDA) has extended by three months the target action date of its review of the new drug application (NDA) of tolebrutinib, an oral and ...
A recently launched campaign starring patients and scientists shows Sanofi in hot pursuit of scientific innovation. | A ...
France's Sanofi said its Dupixent drug jointly developed with Regeneron advanced toward a new indication for chronic hives in the European Union, while the U.S. Food and Drug Administration extended ...
Roche has reported wins for its BTK inhibitor fenebrutinib in a pair of phase 3 studies across two multiple sclerosis (MS) populations. One victory was based on the finding that the candidate was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback